BPTH - צמיחת הכנסות שנתית ב-12 החודשים האחרונים Bio-Path Holdings

Can Bio-Path Holdings (BPTH) overcome the risks of capital dilution and testing delays? Bio-Path Holdings (BPTH) develops RNA-based drugs to combat resistant forms of leukemia. Diversification through DNA technologies expands the scope of future solutions. Year-over-year sales volatility over a rolling 12-month period on the GURU.Markets chart reflects a level of 0.00, confirming the current business expansion trend.

The unique liposomal RNA therapy platform of Bio-Path Holdings (BPTH) requires a constant influx of capital, making the commercialization dynamics of its developments a key value driver. By analyzing the trailing twelve months (TTM) operating revenue growth, an investor assesses the percentage change in revenue over the last twelve months relative to the previous year, which allows them to filter out market noise and timely identify business stagnation risks through the trend shown on this chart.